pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$RVMDRevolution Medicines, Inc.

$RVMD159.43-0.24%
Redwood City, CA, USupdated 8h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
4
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 1Phase 3: 1
1Phase 21Phase 3
Phase 3
daraxonrasib
Non-Small Cell Lung Cancer
Phase 2
elironrasib
Non-Small Cell Lung Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 4, 2026
earnings
$RVMD159.43-0.24%
16d ago
Revolution Medicines, Inc. earnings
Revolution Medicines, Inc.
→
view all catalysts →

Active trials

  • phase3Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)recruitingn=590
  • phase2Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumorsrecruitingn=370
  • phase2Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCrecruitingn=616
  • phase3Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinomarecruitingn=400
  • phase3Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)recruitingn=500
  • phase2Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumorsrecruitingn=534
  • phase3Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )recruitingn=670
  • —Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinomaavailable
🐶 Hiring Signal
345 open roles at Revolution Medicines, Inc. →

Where Revolution Medicines, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 344CNS / Neuroscience 1
departmentCommercial 110Business Development & Sales 62Medical Affairs 26Market Access 20Clinical 20R&D / Discovery 20

News

  • RevMed’s Rasonque shatters analyst estimates with $198M quarter
    Pent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter.
    biospace · 14d ago
  • Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
    With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…
    biospace · 17d ago
  • Alphabet’s GV is one of biotech’s most influential corporate investors
    The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.
    biospace · 23d ago
  • STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
    A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.
    stat · 24d ago
  • Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
    Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review voucher.
    biopharma_dive · 1mo ago
  • Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
    At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xV…
    biospace · 1mo ago
  • Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
    Iambic Therapeutics’ IPO came in dead on target, bringing in $150 million for the AI biotech to fuel the clinical development of its oncology pipeline.
    fiercebiotech · 1mo ago
  • J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
    Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio bu…
    biospace · 1mo ago
  • Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
    Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.
    biospace · 1mo ago
  • New data on RevMed’s Rasonque leave potential opening for other treatments
    Patients with the most common KRAS mutation in pancreatic cancer appeared to have a lower response rate than the overall patient population with Revolution Medicines’ Rasonque, sending the company’…
    endpoints · 1mo ago
view all news mentions →
identifiers
ticker
$RVMD
SEC CIK
0001628171
country
US
source
sec_tickers
top tags
NSCLC2Oncology2
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 27m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?